{"title":"Insilico prediction of anticancer cyanobacterial drug from Nostoc","authors":"M. Sangeetha, M. Menakha, S. Vijayakumar","doi":"10.1016/j.bionut.2013.08.008","DOIUrl":null,"url":null,"abstract":"<div><p><span>The aim of the present study was to predict the anticancer drug<span> from the members of the cyanobacteria. </span></span><span><em>In silico</em></span><span> molecular docking<span> was carried out between the cyanobacterial drug, cryptophycin-F and different types of cancer target proteins. Molecular docking also helped to compare the commercial drug, cabazitaxel with cyanobacterial drug, cryptophycin-F. The energy values produced by the cryptophycin-F with various cancer receptor molecules were ranging from −</span></span> <!-->259.14 to −<!--> <!-->330.01 while, cabazitaxel showed −<!--> <!-->228.18 to −<!--> <!-->385.32. From the above results, it is concluded that cabazitaxel and cryptophycin-F produced more or less similar docking energy with cancer receptor molecules. Therefore, cryptophycin-F, a cyanobacterial drug can be employed as an alternative drug for treating various cancers without any side effects.</p></div>","PeriodicalId":100182,"journal":{"name":"Biomedicine & Preventive Nutrition","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bionut.2013.08.008","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & Preventive Nutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210523913000548","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
The aim of the present study was to predict the anticancer drug from the members of the cyanobacteria. In silico molecular docking was carried out between the cyanobacterial drug, cryptophycin-F and different types of cancer target proteins. Molecular docking also helped to compare the commercial drug, cabazitaxel with cyanobacterial drug, cryptophycin-F. The energy values produced by the cryptophycin-F with various cancer receptor molecules were ranging from − 259.14 to − 330.01 while, cabazitaxel showed − 228.18 to − 385.32. From the above results, it is concluded that cabazitaxel and cryptophycin-F produced more or less similar docking energy with cancer receptor molecules. Therefore, cryptophycin-F, a cyanobacterial drug can be employed as an alternative drug for treating various cancers without any side effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
